RxDoctor Payments Data

John McDonough, MD

Family Medicine · Flemington, NJNPI 1942285549

Payments from drug & device makers

$1,313in general payments, 2019–2025

Across 61 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$300
  • Amarin Pharma, Inc.$172
  • Esperion Therapeutics, Inc.$133
  • Pfizer$106
  • Nestle Healthcare Nutrition Inc.$89
  • AbbVie$80
  • plus $432 from 15 others

What the payments were for

  • Food & beverage$1,313100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,313 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$80,938
Medicare patients
149
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$23,531
JanuviaSitagliptin Phosphate15$18,114
LinzessLinaclotide18$11,811
FarxigaDapagliflozin Propanediol13$9,551
AtacandCandesartan Cilexetil11$6,571
Perindopril Erbumine57$6,320
TradjentaLinagliptin12$6,316
SynthroidLevothyroxine Sodium49$5,015
Carbamazepine ErCarbamazepine12$4,095
Candesartan Cilexetil27$2,938
Advair DiskusFluticasone Propion/Salmeterol12$2,370
Levothyroxine Sodium124$2,339
Acarbose28$2,101
Metoprolol Succinate119$1,959
Citalopram HbrCitalopram Hydrobromide16$1,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$106$24,94432 claims
AbbVieLinzess, Synthroid$80$16,82667 claims
Boehringer IngelheimTradjenta$35$6,31612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →